Plant ID: NPO18473
Plant Latin Name: Plathymenia reticulata
Taxonomy Genus: Plathymenia
Taxonomy Family: Fabaceae
NCBI TaxonomyDB:
148722
Plant-of-the-World-Online:
328385-2
Unknown.
Brazil; Paraguay; Bolivia; Suriname
NPSR1; | |
ACHE; | |
TDP1; MIF; ALOX12; HSD17B1; HSD17B10; NOX4; ALDH1A1; POLB; | |
PIM1; AXL; MET; FLT3; CDK1; KDR; IGF1R; AURKB; CSNK2A1; | |
CA12; CA9; CA7; CA4; | |
ESR2; | |
PTGS1; | |
MMP12; | |
HIF1A; | |
THPO; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.194E-10 | 1.300E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.471E-09 | 4.577E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.760E-09 | 4.792E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4, PTGS1 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.506E-09 | 1.479E-05 | CA12, CA4, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.138E-08 | 4.743E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 6.108E-08 | 6.606E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.375E-07 | 1.032E-04 | ALOX12, CDK1, CSNK2A1, FLT3, HIF1A, IGF1R, KDR, MIF, MMP12, PIM1, THPO |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.706E-07 | 1.548E-04 | ALOX12, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.000E-07 | 2.026E-04 | CA12, CA4, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 8.914E-07 | 3.961E-04 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.130E-07 | 3.976E-04 | CA12, CA4, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 7.860E-06 | 2.223E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 8.303E-06 | 2.318E-03 | AXL, CDK1, CSNK2A1, FLT3 |
BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 1.067E-05 | 2.732E-03 | AXL, CDK1, CYP1A1, CYP1A2, CYP1B1, HIF1A, KDR |
MF | GO:0005488; binding | GO:0042562; hormone binding | 1.296E-05 | 3.173E-03 | ACHE, ALDH1A1, HSD17B1, IGF1R |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.496E-05 | 3.503E-03 | AXL, FLT3, IGF1R, KDR, MET |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.695E-05 | 3.727E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.695E-05 | 3.727E-03 | CYP1A2, CYP2C9 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.178E-05 | 4.651E-03 | CSNK2A1, HIF1A, KDR |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.331E-05 | 4.929E-03 | CA9, CDK1, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FLT3, NOX4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 2.622E-05 | 5.490E-03 | CYP19A1, CYP1A1, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.228E-05 | 8.146E-03 | CYP1A2, CYP2C9 |
BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 4.417E-05 | 8.436E-03 | AXL, FLT3, HIF1A, POLB |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.790E-08 | 6.713E-07 | HSD17B1, CYP1A1, CYP1B1, CYP19A1, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.835E-08 | 9.588E-07 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.439E-08 | 6.713E-07 | CA12, CA4, CA7, CA9 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.873E-06 | 7.261E-05 | CYP2C9, CYP1A2, ALDH1A1, CYP1A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.168E-06 | 9.253E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 9.810E-06 | 1.226E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.879E-05 | 4.156E-04 | CYP1A2, CYP1A1, CYP1B1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.297E-04 | 1.207E-03 | CYP2C9, HSD17B1, CYP1A2, ALDH1A1, CYP1A1, ALOX12, CYP19A1, HSD17B10, PTGS1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.448E-04 | 1.207E-03 | CYP2C9, ALOX12, PTGS1 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 3.348E-04 | 2.092E-03 | KDR, HIF1A, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.824E-04 | 1.368E-03 | FLT3, MET, HIF1A |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.449E-04 | 1.670E-03 | CSNK2A1, MET, IGF1R |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 8.253E-04 | 4.761E-03 | CYP2C9, ALOX12, PTGS1 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 9.112E-04 | 4.881E-03 | THPO, FLT3, KDR, MET |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.042E-03 | 5.212E-03 | CYP2C9, CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; MIF; PTGS1; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; PTGS1; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; HIF1A; CA9; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; CA9; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
NA: NA | Rheumatold arthritis | NA | PTGS1; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
NA: NA | GIST | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CYP19A1; CA9; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; PTGS1; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
NA: NA | Miosis during ocular surgery | NA | PTGS1; |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |